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In the absence of low-level ER-to-mitochondrial Ca2+
transfer, ATP levels fall, and AMPK-dependent,
mTOR-independent autophagy is induced as an
essential survival mechanism in many cell types.
Here, we demonstrate that tumorigenic cancer cell
lines, transformed primary human fibroblasts, and
tumors in vivo respond similarly but that autophagy
is insufficient for survival, and cancer cells die while
their normal counterparts are spared. Cancer cell
death is due to compromised bioenergetics that
can be rescued with metabolic substrates or nucleo-
tides and caused by necrosis associated with mitotic
catastrophe during their proliferation. Our findings
reveal an unexpected dependency on constitutive
Ca2+ transfer to mitochondria for viability of tumori-
genic cells and suggest that mitochondrial Ca2+
addiction is a feature of cancer cells.INTRODUCTION
Inositol 1,4,5-trisphosphate receptors (InsP3Rs) are a ubiquitous
family of Ca2+ release channels present primarily in the ER (Fos-
kett et al., 2007). Ca2+ release through the InsP3R regulates
numerous cell functions, including transcription, proliferation,
secretion, and motility, among others (Ca´rdenas et al., 2005;
Foskett et al., 2007). InsP3R-mediated Ca
2+ signals also regulate
cell metabolism, primarily by supplying released Ca2+ to mito-
chondria, where it stimulates production of reducing equivalents
by pyruvate dehydrogenase (PDH) and two Ca2+ dependent de-Cellhydrogenases in the tricarboxylic acid (TCA) cycle, a-ketogluta-
rate dehydrogenase (a-KGDH) and isocitrate dehydrogenase
(IDH) (McCormack and Denton, 1979), as well as activities of res-
piratory chain components to promote oxidative phosphoryla-
tion (OXPHOS) and ATP production (Murphy et al., 1990; Territo
et al., 2000). Low-level constitutive InsP3R-mediated Ca
2+
release is essential for maintaining basal levels of OXPHOS
and ATP production in a wide variety of cell types (Ca´rdenas
et al., 2010). In the absence of constitutive ER-to-mitochondrial
Ca2+-transfer, ATP levels fall and AMPK-dependent, mTOR
(mammalian target of rapamycin)-independent autophagy is
induced (Ca´rdenas et al., 2010; Mallilankaraman et al., 2012a,
2012b) as an essential survival mechanism (Ca´rdenas et al.,
2010). In all cell types examined, inhibition of constitutive mito-
chondrial Ca2+ uptake induced a bioenergetic crisis that resulted
in a reprogramming of metabolism reminiscent of that induced
by nutrient starvation, despite nutrient availability and enhanced
nutrient uptake.
A hallmark feature of cancer cells is a re-programming of their
metabolism, even when nutrients are available (Boroughs and
DeBerardinis, 2015; Jones and Thompson, 2009; Jose et al.,
2011). All major tumor suppressors and oncogenes have con-
nections with metabolic pathways (Deberardinis et al., 2008;
Koppenol et al., 2011; Levine and Puzio-Kuter, 2010; Vander
Heiden et al., 2009). Warburg suggested that cancer originates
from irreversible injury inmitochondria, followed by a compensa-
tory increase of glycolysis (Warburg, 1956), but increasing evi-
dence indicates that mitochondrial function is essential for
cancer cells (Koppenol et al., 2011). A continuous supply of
metabolic intermediates from the TCA cycle fuels lipid, nucleic
acid, and protein biosynthesis and provides redox power essen-
tial for cancer cell proliferation (Boroughs and DeBerardinis,
2015; Deberardinis et al., 2008). Many tumor cells requireReports 14, 2313–2324, March 15, 2016 ª2016 The Authors 2313
OXPHOS to maintain growth (Birsoy et al., 2014; Caro et al.,
2012) and for the majority of their ATP production (Jose et al.,
2011). Mutations in OXPHOS genes are tumorigenic (Bayley
and Devilee, 2010), and mitochondrial inhibitors have antitumor
activity (Cheng et al., 2012; Momose et al., 2010; Zhang et al.,
2014).
Accordingly, here, we asked what role constitutive mitochon-
drial Ca2+ uptake, important in normal cell bioenergetics, plays
in cancer cell metabolism and viability. Using tumorigenic breast
and prostate cancer cell lines and genetically transformed
isogenic primary human fibroblasts, we found that interruption
of constitutive ER-to-mitochondrial Ca2+ transfer elicited effects
similar to those observed in normal cells, including diminished
OXPHOS, AMPK activation, and induction of autophagy.
Whereas autophagy was sufficient for survival of normal cells, it
was insufficient in cancer cells, which responded strikingly with
massive death, while their normal counterparts were spared.
Furthermore, inhibition of InsP3R activity strongly suppressed
melanoma tumorgrowth inmice.Additionofmetabolic substrates
or nucleotides rescued the lethal effect of inhibitingmitochondrial
Ca2+ uptake, suggesting that cell death was induced by compro-
mised bioenergetics. Cell death was caused by necrosis associ-
ated with mitotic catastrophe at daughter cell separation during
ongoing proliferation of the cancer cells. Our findings reveal a
fundamental and unexpected dependency on InsP3R-mediated
Ca2+ transfer to mitochondria for viability of cancer cells.
RESULTS
Inhibition of InsP3R Activity Creates a Bioenergetic
Crisis in Both Tumorigenic and Non-tumorigenic Cell
Lines
We examined the effects of InsP3R inhibition on metabolic re-
sponses of human breast- and prostate-cancer-derived tumori-
genic cell lines. As controls, we examined non-tumorigenic lines
derived from normal tissues. XeB (5 mM, 1 hr), a specific InsP3R
inhibitor (Jaimovich et al., 2005), reduced basal and maximal ox-
ygen consumption rates (OCRs) (Figure 1A), enhanced AMPK
phosphorylation (P-AMPK) (Figure 1B), and induced autophagic
flux in both non-tumorigenic and tumorigenic breast (Figures 1C,
S1A, and S1B) and prostate (Figures S2A and S2B) cell lines. The
effects of XeB on bioenergetic parameters were dose depen-
dent, with 5 mM as the minimum concentration required to
strongly induce autophagy and significantly reduce basal and
maximal OCRs in both MCF10A and MCF7 cells (Figures S1C–
S1F). Similar responses to InsP3R inhibition, including decreased
OCR, increased P-AMPK, and induction of autophagy were
observed in mouse melanoma B16F10 cells (Figures S2F–
S2H), demonstrating that this is a non-species-specific general
phenomenon. Thus, XeB generates similar bioenergetic crises
in tumorigenic and non-tumorigenic cell lines. XeB inhibited
constitutive and spontaneous Ca2+ transients in both MCF10A
and MCF7 cells (Figures 1D and S1G; Movie S1 [MCF7]; Movie
S2 [MCF10A]). Furthermore, simultaneous genetic knockdown
(KD) of InsP3R types 1 and 3 (50%–70%efficiency; Figure S1H),
the main isoforms expressed in these cells (Figures S1I–S1K),
created a similar bioenergetic crisis in normal and tumorigenic
cells (Figures 1E and 1F).2314 Cell Reports 14, 2313–2324, March 15, 2016 ª2016 The AuthorInhibition of InsP3R Activity Is Toxic, Specifically for
Tumorigenic Cells
Breast cells were treated with XeB for 24 hr, and cell viability was
assessed by flow cytometry. 2.5 mMXeB had little effect, except
for tumorigenic HS578T cells, in which death was enhanced by
8% ± 1% (Figure 2A). In contrast, 5 mM XeB induced substantial
death by 43% ± 4% and 53% ± 2% in tumorigenic MCF7 and
T47D cell lines, respectively, and over 22% ± 1% in HS578T
cells. In contrast, non-tumorigenic MCF10A cells showed only
limited sensitivity (5% ± 0.4% cell death). At 10 mM, XeB killed
63% ± 7% and 64% ± 5%of MCF7 and T47D cells, respectively,
and 42% ± 6%of HS578T cells, whereas MCF10A cells had only
modest sensitivity (24%± 1%) (Figure 2A). Similar XeB-mediated
killing was observed in human-cancer-derived prostate cell lines
PC3 and DU145, but there was little effect for the non-tumori-
genic PNT2 prostate line (Figure S2C). In agreement with results
from flow cytometry, XeB caused striking lactate dehydrogenase
(LDH) release in all tumorigenic breast lines, compared with
MCF10A cells (Figure 2B), as well as in mouse melanoma
B16F10 cells (Figure S2I). As assessed by both flow cytometry
and LDH release (Figures 2C and 2D), tumorigenic lines started
dying as early as at 6 hr of exposure to 5 mM XeB, while the
non-tumorigenic cells remained insensitive. The observed differ-
ences in XeB sensitivity could not be accounted for by intrinsic
differences in proliferation rates between cell lines in untreated
conditions (Figures S1L andS2E). Tumorigenic breast (Figure 2E)
and prostate (Figure S1D) cells exposed to XeB (5 mM for 24 hr)
displayed strikingmorphological changes, including rounding up
and shrinkage, whereas similarly treated non-tumorigenic cells
maintained normal morphology.
These results suggest that tumor cell survival is dependent
upon InsP3R signaling. In agreement, inhibition of phospholipase
C (PLC), the enzyme responsible for the generation of the InsP3R
ligand InsP3, with U73122 (2 mM), but not the inactive analog
U73343, caused striking LDH release in all tumorigenic breast
cell lines, with substantially less effects in the non-tumorigenic
line (Figure 2F). Similarly, simultaneous genetic KD of InsP3R
types 1 and 3 caused comparable LDH release as XeB and
U73122 in MCF7 and T47D cells, while non-tumorigenic
MCF10A cells showed only a small increase (Figure 2G). Thus,
tumorigenic cell lines appear to have an essential dependence
on InsP3R-mediated Ca
2+ signaling for survival, unlike normal
cells.
Inhibition of InsP3R Activity Reduces the Proliferative
Potential of Cancer Cell Lines
Colony formation is a hallmark of cancer cells that reflects their
ability to proliferate indefinitely (Munshi et al., 2005). XeB
(5 mM, 24 hr) diminished colony formation by tumorigenic breast
MCF7 (Figure 3A) and T47D cells and prostate PC3 cells (Figures
S3A and S3B). In normal cells, the bioenergetic crisis caused by
inhibition of InsP3R activity could be overcome by providing
pyruvate as a mitochondrial substrate, presumably by mass ac-
tion to drive flux through the system (Ca´rdenas et al., 2010).
Methyl-pyruvate (5 mM, 24 hr) rescued the XeB-induced MCF7
colony formation defect (Figure 3B). Pyruvate has antioxidant
properties (Andrae et al., 1985). However, XeB did not enhance
reactive oxygen species (ROS) production (Figure S3C), ands
Figure 1. Inhibition of InsP3R Activity Re-
duces Oxygen Consumption and Activates
AMPK-Dependent Autophagy
(A) Basal and maximal OCRs of non-tumorigenic
and tumorigenic breast cell lines incubated with
5 mM XeB for 1 hr. n = 3, mean ± SEM. *p < 0.05;
**p < 0.01 (Student’s t test).
(B) Representative western blots of P-AMPK and
total AMPK in non-tumorigenic and tumorigenic
breast cell lines incubated with 5 mM XeB for 1 hr.
Bar graph: P-AMPK/AMPK expressed as average
fold increase over basal levels (control cells). n = 5,
mean ± SEM. **p < 0.01; ***p < 0.001 (Student’s
t test).
(C) Representative western blots of autophagy
marker LC3 or tubulin as loading control in non-
tumorigenic and tumorigenic breast cell lines
treated with 5 mM XeB (1 hr) and quantification of
LC3-II/tubulin expressed as fold increase over
basal levels (control cells). n = 5, mean ± SEM.
**p < 0.01; ***p < 0.001 (Student’s t test).
(D) Representative fluorescence recordings of
Ca2+ release events in unstimulated MCF7 and
MCF10A cells treated (or not treated) with 5 mM
XeB (see also Movies S1 and S2).
(E) Representative western blots of AMPK in breast
lines transiently transfected with a small interfering
RNA (siRNA) against both type 1 and type 3 InsP3R
(KD) or non-target scrambled (S) siRNA for 24 hr.
Bar graph: P-AMPK/AMPK expressed as average
fold increase over basal levels (S cells). n = 3,
mean ± SEM. *p < 0.05; **p < 0.01 (Student’s
t test).
(F) Representative western blots of LC3 or tubulin
in breast cells transiently transfected with a siRNA
against type 1 and type 3 InsP3R (KD) or a non-
target (S) siRNA for 24 hr and quantification of
LC3-II/tubulin expressed as average fold increase
over basal levels (S cells). n = 3, mean ± SEM.
***p < 0.001 (Student’s t test).
See also Figure S1 and Movies S1 and S2.N-acetylcysteine (NAC) (5 mM, 24 hr) did not rescue colony for-
mation (Figure 3B) or prevent XeB-induced AMPK activation
(Figure S3D), autophagy (Figure S3E), or MCF7 cell death (Fig-
ure S3F). These results suggest that cancer cell killing and reduc-
tion of colony formation by inhibition of InsP3R activity is a
consequence of a bioenergetic crisis that can be rescued by a
mitochondrial substrate, but not by an antioxidant.
XeB Induces Cell Death in Transformed, But Not
Isogenic Control, Human Fibroblasts
Although the cell lines are well validated and broadly used
models, the fact that the control lines are also transformed com-
plicates the results. Therefore, we turned to an isogenic primary
human fibroblast model. Primary human fibroblasts were trans-
formed by the incorporation of oncogenic HRasG12V while by-
passing retinoblastoma (Rb)-mediated G1 cell-cycle restraint
by enforced expression of cyclin-dependent kinase-4 (Cdk4)
(Ridky et al., 2010). This model (HrasG12V-CDK4) has classicCellcancer features, including invasive properties. HrasG12V-
CDK4 fibroblasts showed elevated glucose consumption (Fig-
ure S3G) and lactate release (Figure S3H), consistent with
acquisition of aWarburg-typemetabolism. Nevertheless, control
and transformed cells had comparable OCRs, suggesting similar
OXPHOS (Figure 4A). Furthermore, the OCR was reduced by
XeB to a similar extent in HrasG12V-CDK4 and isogenic control
cells (Figure 4A), and a bioenergetic crisis ensued, as evidenced
by increased P-AMPK and induction of autophagy (Figures 4B
and 4C). These results suggest that mitochondria remain impor-
tant for maintenance of cell bioenergetics in these primary trans-
formed cells.
As in the cancer cell lines, XeB induced profound morpholog-
ical changes and reduced the number of HrasG12V-CDK4 cells
per field, whereas isogenic controls behaved similarly to vehicle-
treated cells (Figure S3I). LDH release was enhanced 6-fold
in HrasG12V-CDK4 cells, compared with isogenic controls (Fig-
ure 4D). The sensitivity of HrasG12V-CDK4 cells compared withReports 14, 2313–2324, March 15, 2016 ª2016 The Authors 2315
Figure 2. Inhibition of InsP3R Causes Death
of Tumorigenic Breast Cell Lines
(A) Non-tumorigenic and tumorigenic human
breast cell lines were treated with XeB for 24 hr,
and cell death was determined by TOTO-3 incor-
poration by flow cytometry. n = 3, mean ± SEM.
***p < 0.001; NS, not significant (one-way ANOVA
followed by Dunnett’s multiple comparison post
test).
(B) Breast cell lines were treated with 5 mMXeB for
24 hr, and cell death was determined by LDH
release. n = 3, mean ± SEM. *p < 0.05; ***p < 0.001
(Student’s t test).
(C) Time course of cell death determined by
TOTO-3 incorporation by flow cytometry in human
breast cell lines treated with 5 mM XeB. n = 3,
mean ± SEM. *p < 0.05; ***p < 0.001 (Student’s
t test).
(D) Time course of cell death determined by LDH
release in breast cell lines treated with 5 mM XeB.
n = 3, mean ± SEM. *p < 0.05; ***p < 0.001 (Stu-
dent’s t test).
(E) Differential interference contrast (DIC) images
of breast cell lines derived from non-tumorigenic
(MCF10A) or tumorigenic (MCF7, T47D, HS578T)
human tissue treated with 5 mM XeB for 24 hr.
Scale bar represents 10 mm. n = 3.
(F) Non-tumorigenic and tumorigenic breast cell
lines were treated with 2 mM of the PLC inhibitor
U73122 or its inactive analog U73343 for 12 hr, and
cell death was determined by LDH release. n = 3,
mean ± SEM. ***p < 0.001; NS, not significant
(Student’s t test).
(G) Cell death (LDH release) in human breast cell
lines transiently transfected with a siRNA against
type 1 and type 3 InsP3R (IP3R KD) or a scrambled
non-target (S) siRNA for 24 hr. n = 3, mean ± SEM.
***p < 0.001; NS, not significant (Student’s t test).
See also Figure S1.that of isogenic cells could not be accounted for by differences
in their normal rates of proliferation (Figure S3J). Simultaneous
KD of InsP3R types 1 and 3, the main isoforms in these cells (Fig-
ures S4A–S4D) enhanced P-AMPK and autophagy in both
HrasG12V-CDK4 and isogenic control fibroblasts (Figure 4E
and 4F), but it caused significant death, specifically in the
HrasG12V-CDK4 cells (Figure 4G). Thus, in primary human cells,
as in breast and prostate cell lines, inhibition of InsP3R activity is
strongly toxic specifically for cancer cells.
Killing of Cancer Cells by Inhibition of InsP3R Activity Is
Mediated by Altered Mitochondrial Function
In normal cells, inhibition of mitochondrial Ca2+ uptake pheno-
copies the effects of InsP3R inhibition on cell bioenergetics, sug-
gesting that the primary role of InsP3R activity in preserving
normal cellular bioenergetics is to provide Ca2+ to mitochondria
(Mallilankaraman et al., 2012a). The similar bioenergetic re-
sponses to inhibition of InsP3R activity of tumor cell lines and2316 Cell Reports 14, 2313–2324, March 15, 2016 ª2016 The AuthorHrasG12V-CDK4 cells suggested that cancer cells may have a
similar dependence on constitutive mitochondrial Ca2+ uptake.
To test this, we knocked down in HrasG12V-CDK4 and isogenic
control cells the expression of MCU, the pore-forming subunit
of the mitochondrial uniporter Ca2+ channel, the major Ca2+ up-
take pathway in mitochondria (Foskett and Philipson, 2015).
MCU expression was similar in human normal versus trans-
formed fibroblasts or between the MCF10A and MCF7 cells
(Figures S4E and S4F). MCU KD (Figure S4E) increased
P-AMPK and induced autophagy (Figures 4E and 4F), as in
normal cells (Mallilankaraman et al., 2012a, 2012b). Importantly,
MCU KD enhanced killing preferentially of the HrasG12V-CDK4-
transformed cells (Figure 4G). In contrast, overexpression of
MCU was unable to protect MCF7 cells from death induced by
InsP3R inhibition with XeB (Figures S4G and S4H). These results
suggest that InsP3R-mediated Ca
2+ release and its transfer to
mitochondria through MCU are essential to maintain cancer
cell viability.s
Figure 3. Inhibition of InsP3R Signaling Im-
pairs Colony Formation in the MCF7 Tumor-
igenic Breast Cell Line
(A) Representative plates of MCF7 cells treated
with 5 mM XeB or vehicle (top) and quantitative
analysis of colony numbers (bottom). n = 3, mean ±
SEM. ***p < 0.001 (Student’s t test).
(B) Representative plates of MCF7 cells treated
with 5 mM XeB, 5 mM methyl-pyruvate, 5 mM
XeB + 5mMmethyl-pyruvate, or 5 mMXeB + 5 mM
n-acetylcysteine (NAC) (top) and quantitative
analysis of colony numbers (bottom). n = 3, mean ±
SEM. **p < 0.001; ***p < 0.001; NS, not significant
(Student’s t test).
See also Figure S2.The TCA cycle is regulated by product inhibition, substrate
availability, and cofactors, including Ca2+. PDH, IDH, and
a-KGDH activities are all critically regulated by mitochondrial
matrix Ca2+ (Glancy and Balaban, 2012). Inhibition of InsP3R-
mediated Ca2+ release reduces PDH activity, resulting in
decreased OCR and ATP production (Ca´rdenas et al., 2010).
Cancer cells rely on mitochondria for production of TCA interme-
diates needed for high growth and proliferation (Boroughs and
DeBerardinis, 2015). We speculated that inhibition of mitochon-
drial function by the absence of sufficient matrix Ca2+ cannot be
compensated for, specifically in cancer cells, because of this
dependence on the TCA cycle. Addition of dimethyl a-KG or
methyl-pyruvate, two substrates that energize mitochondria
(Ca´rdenas et al., 2010; Wise and Thompson, 2010) to XeB-
treated (5 mM, 24 hr) fibroblasts strongly reduced cell death (Fig-
ure 4H). Protection was unrelated to antioxidant properties of the
substrates, since NAC (5 mM) was without effect on XeB-
induced P-AMPK (Figures S4I and 4K), autophagy (Figures S4J
and S4L), or killing (Figure S4M).
Although enhanced P-AMPK indicates that inhibition of
InsP3R-mediated Ca
2+ transfer to mitochondria lowers cellular
ATP (Ca´rdenas et al., 2010), glycolysis is believed to provide suf-
ficient ATP for cancer cell functions (Deberardinis et al., 2008).
However, as highly proliferative cells, cancer cells rely on the
TCA cycle for the production of metabolic intermediates for the
generation of fatty acids and nucleotides. At least three mito-
chondrial pathways are involved in pyrimidine and purine
nucleotide synthesis, and the rate-limiting step in de novo syn-
thesis of pyrimidines occurs in mitochondria and is linked to
respiratory chain activity (Desler et al., 2010). To determine
whether mitochondrial hypo-function in response to InsP3R inhi-Cell Reports 14, 2313–2324bition compromises nucleotide meta-
bolism that may contribute to cancer cell
death, HrasG12V-CDK4 fibroblasts were
treated with 5 mM XeB for 24 hr in media
supplemented with nucleosides. Notably,
nucleoside supplementation was strongly
protective of XeB-treated HrasG12V-
CDK4 cells (Figure 5A), despite enhanced
P-AMPK phosphorylation and autophagy
activation (Figures 5B–5E). Thus, with
nucleoside supplementation, cancer cellsbehave as normal cells, surviving in the face of an unfavorable
bioenergetic state.
Nucleosides contribute to the purine and pyrimidine genera-
tion necessary for DNA synthesis. In normal fibroblasts, XeB
(5 mM, 10 hr) reduced bromodeoxyuridine (BrdU) incorporation
by >50% (Figure 5F), suggesting that the unfavorable bioener-
getic state in the absence of Ca2+ transfer to mitochondria
slowed cell proliferation, as expected. In marked contrast, XeB
had minimal effects on BrdU incorporation into HrasG12V-
CDK4 cells (Figure 5G). These results suggest that normal cells
restrain entry into the S phase when conditions are unsuitable,
but transformed cells do not recognize this checkpoint. Because
of the enforced expression of Cdk4 in HrasG12V-CDK4 cells, it
remained unclear whether other cancer cells would progress
similarly into mitosis during a XeB-induced compromised bioen-
ergetic state. XeB (5 mM, 24 hr) increased the population of
MCF10A cells in the G1 phase that correlated with a decrease
proceeding through the S phase (Figure 5H), as observed in
normal human primary fibroblasts. In contrast, MCF7 cells
showed no increase of the G1 population and only a slight
decrease in cells in the S phase (Figure 5I). This suggests that
MCF7 cells, like HrasG12V-CDK4 cells but unlike normal cells,
proceed through the cell cycle, despite their compromised bio-
energetic state. Similar behavior was observed in HeLa cells, a
common cervical tumor cell line (Figure 5J).
HeLa cells were optically imaged to observe progression
through the cell cycle. Remarkably, XeB-treated cells entered
mitosis but then collapsed catastrophically and died during
daughter cell separation (n = 30 mitoses) (Figure 5L; Movie S3),
a phenotype never observed in vehicle-treated cells (n = 50 mi-
toses). This suggests that, in cells with InsP3R activity inhibited, March 15, 2016 ª2016 The Authors 2317
Figure 4. Pharmacological and Genetic In-
hibition of InsP3R Causes Death of Primary
HRasG12V-Cdk4 Transformed Human Fi-
broblasts
(A) Top: representative traces of OCR in normal
(black) or transformed (red) fibroblasts treated
(black circles, red upside-down triangles) or not
(black squares, red triangles) with 5 mM XeB for
1 hr. a: injection of 1 mM oligomycin; b: 300 nM
FCCP; c: 100 nM rotenone. Bottom: summary of
basal and maximal OCRs in fibroblasts treated, or
not treated, with 5 mM XeB for 1 hr. n = 3, mean ±
SEM. ***p < 0.001.
(B) Representative western blots of AMPK in
normal (N) and transformed (T) fibroblasts treated
with 5 mM XeB (1 hr). Bar graph: P-AMPK/AMPK
expressed as average fold increase over basal
levels (control cells). n = 6, mean ± SEM. ***p <
0.001 (Student’s t test).
(C) Representative western blots of LC3 and
tubulin in normal (N) and transformed (T) fibro-
blasts treated with 5 mM XeB for 1 hr. Bar graph:
LC3-II/tubulin expressed as average fold increase
over basal levels (control cells). n = 6, mean ±
SEM. ***p < 0.001 (Student’s t test).
(D) Determination of cell death by LDH release in
normal and transformed fibroblasts treated with
2.5 or 5 mM XeB (24 hr). n = 3, mean ± SEM. ***p <
0.001; NS, not significant (Student’s t test).
(E) Representativewestern blots of AMPK in normal
(N) and transformed (T) fibroblasts transiently
transfected with a siRNA against type 1 and type 3
InsP3R (IP3R) for 24 hr or siRNA against MCU for
72 hr. Bar graph: P-AMPK/AMPK expressed as the
average fold increase over basal levels (S cells).
n = 3, mean ± SEM. ***p < 0.001 (Student’s t test).
(F) Representative western blots of LC3 and
tubulin in normal (N) and transformed (T) fibro-
blasts transiently transfected with a siRNA against
type 1 and type 3 InsP3R for 24 hr or siRNA against
MCU for 72 hr, or scrambled sRNAs (S); LC3-II/
tubulin expressed as average fold increase over
basal levels (S cells). n = 3, mean ± SEM. ***p <
0.001 (Student’s t test).
(G) Determination of cell death by LDH release in normal and transformed fibroblasts transiently transfected with a siRNA against type 1 and type 3 InsP3R for
24 hr or siRNA against MCU for 72 hr. n = 3, mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t test).
(H) Determination of cell death by LDH release in normal and transformed fibroblasts treated simultaneously with 5 mM XeB and either 5 mM methyl-pyruvate
(Pyr) or 5 mM dimethyl a-KG (Keto) for 24 hr. n = 3, mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; NS, not significant (Student’s t test).
See also Figure S4.or mitochondrial Ca2+ uptake otherwise blocked, cancer cells
progress through the cell cycle, despite their bioenergetic crisis,
in contrast to normal cells that stop in the G1 phase, and their
progression into mitosis appears to be a step that results in
cell death. To probe this further, MCF7 cells were incubated
with 400 mM hydroxyurea (HU) to arrest them in the S phase of
the cell cycle (Figure S5A) and then were treated with 5 mM
XeB for 24 hr. As shown in Figure 5K, the prevention of cell-cycle
progression strongly decreased cell death induced by XeB.
Cell Death Inducedby Inhibition of InsP3RCa
2+ Signaling
Is Mainly Necrotic
Our results reveal that inhibition of InsP3R-mediated Ca
2+ trans-
fer to mitochondria causes death, specifically in tumorigenic2318 Cell Reports 14, 2313–2324, March 15, 2016 ª2016 The Authorcells, but how they die is unknown. Autophagy inhibition with
3-methyladenine (3MA) (Figures S5B and S5C) did not prevent
cell death in XeB-treated MCF7 and MCF10A cells (Figure 6A)
and in normal and HrasG12V-CDK4 fibroblasts (Figure 6B), sug-
gesting that autophagy is not driving cell death. Although 3MA
tended to increase cell death in XeB-treated MCF10A cells and
normal fibroblasts, suggesting that autophagy plays a cell sur-
vival role, as previously suggested (Ca´rdenas et al., 2010), KD
of ATG7 (Figures S5D and S5E) did not influence the extent of
cell death (Figure S5F). Inhibition of apoptosis with the pan-cas-
pase inhibitor Z-VAD-FMK did not protect tumorigenic cells from
XeB-induced death (Figures 6A and 6B). Furthermore, western
blot and immunofluorescence analyses of activated cleaved
caspase-3 in human normal and HrasG12V-CDK4 fibroblastss
Figure 5. Nucleoside Rescue of Cancer Cell
Killing and Cell Cycle Defects by Inhibition
of InsP3R Activity
(A) Normal and transformed fibroblasts were
treated with 5 mM XeB in the absence or presence
of nucleosides (NUC) for 24 hr, and cell death was
determined by LDH release. n = 3, mean ± SEM.
**p < 0.01 (Student’s t test).
(B) Representative western blots of AMPK in
normal fibroblasts treated with 5 mMXeB for 1 hr in
the presence or absence of nucleosides (NUC).
Bar graph: P-AMPK/AMPK expressed as average
fold increase over basal levels (control cells). n = 3,
mean ± SEM. ***p < 0.001; NS, not significant
(Student’s t test).
(C) Same as in (B), using transformed fibroblasts.
n = 3, mean ± SEM. ***p < 0.001; NS, not signifi-
cant (Student’s t test).
(D) Representative western blots of LC3 and
tubulin in normal fibroblasts treated with 5 mMXeB
for 1 hr in the presence or absence of nucleosides
(NUC). Bar graph: LC3-II/tubulin expressed as
average fold increase over basal levels (control
cells). n = 3; mean ± SEM. ***p < 0.001; NS, not
significant (Student’s t test).
(E) Same as in (D), using transformed fibroblasts.
n = 3, mean ± SEM. ***p < 0.001 (Student’s t test).
(F) BrdU incorporation in normal fibroblasts
treated with 5 mM XeB for 12 hr. Top: BrdU
immunofluorescence. Bottom: BrdU labeling ex-
pressed as percentage of control. n = 3, mean ±
SEM. ***p < 0.001 (Student’s t test). Scale bar
represents 10 mm.
(G) Same as in (F), using transformed fibroblasts.
n = 3, mean ± SEM. *p < 0.05 (Student’s t test).
Scale bar represents 10 mm.
(H) Cell-cycle profile determined by flow cytometry
in MCF10A cells treated, or not treated, with 5 mM
XeB for 24 hr, showing percentage of cells in each
phase. n = 3, mean ± SEM. **p < 0.001; NS, not
significant.
(I) Cell-cycle profile in MCF7 cells treated, or not
treated, with 5 mM XeB for 24 hr, showing the
percentage of cells in each phase. n = 3, mean ±
SEM. *p < 0.05, NS: not significant.
(J) As in (I), using HeLa cells. n = 3, mean ± SEM.
NS: not significant.
(K) Cell death was determined by PI incorporation
by flow cytometry of MCF7 cells treated, or not
treated, with 5 mM XeB for 24 hr after a 48-hr treatment with 400 mM HU. n = 3, mean ± SEM. **p < 0.001; NS, not significant (Student’s t test).
(L) DIC images of HeLa cells loaded with 8 nM TMRE. XeB (5 mM) was added at time 0h0’; images were collected at indicated times. Arrow shows dividing cell.
Scale bar represents 10 mm.
See also Movie S3.(Figure S5G), and in tumor samples (Figure S5H), similarly sug-
gested that apoptosis is not a major feature associated with
cell killing. Flow cytometry analyses using fluorescein isothiocy-
anate (FITC)-Annexin V and propidium iodide (PI) labeling further
confirmed the presence of only a small apoptotic cell population
after XeB treatment (Figure S5I). Inhibition of necroptosis with
necrostatin also did not prevent XeB-induced cell death (Figures
6A and 6B). The transcription factor HMGB1 is normally localized
in the nucleus but is released into the cytoplasm during early
stages of necrosis (Scaffidi et al., 2002).Most (>50%)MCF7 cells
exposed to 5 mM XeB for 24 hr lost nuclear labeling, while un-Celltreated cells and treated MCF10A cells overwhelmingly main-
tained nuclear HMGB1 labeling (Figures 6C and 6D). Together
with the imaging data, these results suggest that, in response
to the inhibition of Ca2+ transfer to mitochondria, cancer cells
die by necrosis, at approximately the time of daughter cell sep-
aration in mitosis.
Inhibition of InsP3R Activity Impairs Tumor Growth in
Nude Mice
To evaluate whether InsP3R inhibition affected tumor growth
in vivo, subcutaneous tumors were generated using B16F10Reports 14, 2313–2324, March 15, 2016 ª2016 The Authors 2319
Figure 6. Inhibition of InsP3R Activity Kills
Cancer Cells by Necrosis but Not by Auto-
phagy, Apoptosis, or Necroptosis
(A) Non-tumorigenic (MCF10A) and tumorigenic
(MCF7) breast cell lines were treated with 5 mM
XeB for 24 hr in the presence or absence of the
apoptosis inhibitor Z-VAD-FMK (20 mM), auto-
phagy inhibitor 3-MA (10 mM), or necroptosis
inhibitor nec-1 (20 mM), and cell death was deter-
mined by LDH release. n = 3, mean ± SEM. NS: not
significant (Student’s t test).
(B) Same as in (A) for normal and transformed
primary human fibroblasts. n = 3, mean ± SEM.
NS, not significant (Student’s t test).
(C) HMGB1 immunofluorescence in MCF7 and
MCF10A cells treated with 5 mM XeB or vehicle for
24 hr. Note that most nuclear label is absent in
treated MCF7 cells. Scale bar represents 10 mm.
(D) Quantification of loss of nuclear HMGB1 ex-
pressed as percent increase over control. n = 3,
mean ± SEM. ***p < 0.001 (Student’s t test).melanoma cells. As described earlier, treatment of B16F10 cells
in vitro with 5 mM XeB induced AMPK phosphorylation and acti-
vated autophagy (Figures S2F and S2G). OCRwas inhibited (Fig-
ure S2H), and LDH release was increased in a dose-dependent
manner by a 24-hr exposure to XeB (Figure S2I). Thus, this cell
line is appropriate to examine in vivo. B16F10 cells were injected
subcutaneously into ventral flanks of 5- to 6-week-old nu/nu
mice. When tumors were palpable, usually by day 5 post-injec-
tion, one tumoral flank was injected with 100 ml of a solution of
100 mM XeB, and the other was injected with vehicle (PBS plus
ethanol). One day later, mice were euthanized, and tumors
were extracted and weighed (Figure S6A, treatment 1). XeB
reduced tumor size by nearly 60% in comparison to untreated tu-
mors (Figure 7A). In a different paradigm, one tumoral flank was
treated every other day for a week with 100 ml of a solution of
100 mM XeB (Figure S6A, treatment 2). XeB reduced tumor size
by70%, compared with untreated tumors (Figure 7B). Markers
of bioenergetic stress normally observed after InsP3R inhibition,
including enhanced AMPK phosphorylation and autophagy,
were observed in the XeB-injected tumor sections (Figures
S6B and S6C). The vast majority of XeB-treated tumor cells
lost HMGB1 nuclear localization, whereas control tumor cells
had HMGB1 largely in the nucleus (Figure 7C). Ki67, a marker
of cell proliferation, labeled nuclei equivalently in both XeB-
and vehicle-treated tumors (Figure 7D), consistent with the
idea that tumor cells remain committed to enter the cell cycle,
even when in a state of compromised bioenergetics caused by
inhibition of InsP3R activity.2320 Cell Reports 14, 2313–2324, March 15, 2016 ª2016 The AuthorsDISCUSSION
The main result of the present study is the
demonstration of a unique requirement of
tumorigenic cancer cells for constitutive
ER-to-mitochondria Ca2+ transfer for their
survival. In the absence of this transfer,
either as a consequence of blocking
InsP3R-mediated Ca
2+ release or block-ing mitochondrial Ca2+ uptake, all tumor cells examined experi-
enced a bioenergetic crisis similar to that of normal cells, but
activation of autophagy, which enabled normal cells to survive,
was insufficient, and the tumor cells died by necrosis as they
proceeded through mitosis. Specific cancer cell killing was
observed in human tumorigenic cell lines derived from breast,
prostate, and cervix (HeLa), as well as, in data not shown,
bone (143B), colon (SW480 and Colo320), kidney (RCCC), skin
(WM3918, A231, WM239a, and B16F10), and brain (T98G) can-
cers. In addition, the same effect was observed in isogenic pri-
mary human fibroblasts transformed by expression of oncogenic
Ras and enforced expression of Cdk4, a relevant combination
found in spontaneous human cancers (Ridky et al., 2010).
Furthermore, inhibition of InsP3R activity had strong anti-tumor
efficacy in vivo.
Increased InsP3R expression and/or activity has been associ-
ated with cancer cell proliferation, growth, survival, and migra-
tion (Davis et al., 2013; Kang et al., 2010; Messai et al., 2014;
Shibao et al., 2010; Szatkowski et al., 2010). Furthermore,
MCU is highly expressed in ER-negative and basal-like breast
cancers (Sørlie et al., 2006). Our results suggest that the fatal
fate of cancer cells after InsP3R inhibition is a result of mitochon-
drial dysfunction, but it is independent of apoptotic mechanisms
and, instead, appears linked to metabolic defects. Constitutive
InsP3R-mediated Ca
2+ release is essential to support activity of
PDH, a key enzyme that controls the flux of carbon into the
TCA cycle, through Ca2+ activated PDH phosphatase activity.
Consequently, diminished TCA production of NADH leads to
Figure 7. Inhibition of InsP3R Retards Tu-
mor Growth In Vivo
Tumors were generated by subcutaneous injec-
tion of murine-melanoma-derived B16F10 cells
into nude mice.
(A) Tumor weight in mice with tumors injected with
100 ml of a 100-mM XeB solution 1 day before eu-
thanization. n = 9, mean ± SEM. *p < 0.05 (Stu-
dent’s t test).
(B) Tumor weight in mice with tumors injected with
100 ml of a 100-mM XeB solution or vehicle every
other day for 6 days before euthanization. n = 9,
mean ± SEM. *p < 0.05 (Student’s t test).
(C) HMGB1 immunofluorescence in tumors in-
jected, or not injected, with 100 ml of a 100-mMXeB
solution 1 day before euthanization. The control
tumor shows strong nuclear labeling (arrows),
while in the XeB-treated tumor, the nuclei appear
empty (arrows),with remaining labelingcytosolic or
extracellular. n = 3. Scale bar represents 10 mm.
(D) Ki67 immunofluorescence in tumors injected,
or not injected, with 100 ml of a 100-mM XeB so-
lution 1 day before euthanization. Left: panoramic
view of control and XeB-treated tumors. Scale
bar represents 100 mm. Right: detail of control
and XeB-treated tumors. Scale bar represents
10 mm. n = 3.
See also Figure S6.lower rates of OXPHOS and a decline in ATP levels (Ca´rdenas
et al., 2010). It is now recognized that most cancer cells rely on
mitochondrial metabolism and use a significant fraction of
glucose-derived pyruvate for ATP generation and for anaplerotic
reactions to replenish TCA-cycle precursors for macromolecular
biosynthesis (Ahn andMetallo, 2015; Jose et al., 2011; Koppenol
et al., 2011;Moreno-Sa´nchez et al., 2007; Porporato et al., 2014).
OXPHOS is important for ATP production in many cancers (Van-
der Heiden, 2013). Pancreatic cancer (Viale et al., 2014) and
leukemic (Lagadinou et al., 2013; Nakada et al., 2010; Shi
et al., 2012; Skrtic et al., 2011; Yang et al., 2011) stem cells,
diffuse large B cell tumors (Caro et al., 2012), and primary glio-
blastoma sphere cultures (Janiszewska et al., 2012) rely on
OXPHOS for survival. Primary human glioblastomas oxidize
glucose via PDH and the TCA cycle during aggressive tumor
growth (Marin-Valencia et al., 2012). Inhibition of complex 1 in-
hibits respiration and human cancer cell growth (Wheaton
et al., 2014). The TCA cycle is also critically important in cancer
cells for the generation of biochemical intermediates to sustain
high rates of proliferation (Deberardinis et al., 2008). Most cancer
cells derive lipogenic acetyl-coenzyme A (CoA) from pyruvate
through Ca2+-dependent PDH (Hatzivassiliou et al., 2005; Met-
allo et al., 2012), and activation of PDH can promote cancer
cell senescence (Kaplon et al., 2013). Some cancers have defec-
tive OXPHOS but, nevertheless, rely on the TCA cycle (Mullen
et al., 2012, 2014). Even in cancer cells with mutations in the
TCA cycle, the turnover of TCA cycle intermediates is maintained
(Mullen et al., 2012). Most cancer cells use PDH as well as gluta-
mine to fuel the TCA cycle (DeBerardinis et al., 2007), where it en-
ters and then cycles through a-KGDH as the first step (Mullen
et al., 2014). Importantly, a-KGDH activity is strongly Ca2+
dependent (Armstrong et al., 2014), with apparent affinity similarCellto that of PDH phosphatase, suggesting that it may also be
reduced by interruption of ER-to-mitochondria Ca2+ transfer.
Reductive carboxylation of a-KG is observed in many cancer
cells with impaired OXPHOS, where it maintains levels of biosyn-
thetic intermediates. Notably, reductive carboxylation of a-KG
requires its oxidation by Ca2+-dependent a-KGDH (Mullen
et al., 2014). Furthermore, reduction of a-KG to isocitrate is
mediated by IDH, the other Ca2+ dependent enzyme in the
TCA cycle. It is of interest that nucleotide supplementation pre-
vented cancer cell death. a-KG is a precursor for glutamine
and aspartate necessary for pyrimidine synthesis that requires
mitochondrial dihydrooroate, which, in turn, requires flux through
the electron transport chain (Grassian et al., 2014; Mullen et al.,
2014). Together, these data suggest that cancer cells, by virtue
of their reliance on OXPHOS and the TCA cycle for their viability,
have a fundamental reliance on ER-to-mitochondria Ca2+ trans-
fer via activation of Ca2+-dependent dehydrogenases that fuel
key steps in the TCA cycle and OXPHOS.
Normal cells also rely on OXPHOS and the TCA cycle, but, un-
like the cancer cells examined, interruption of constitutive ER-to-
mitochondria Ca2+ transfer had little effect on their viability, in
agreement with previous observations (Ca´rdenas et al., 2010).
Normal cells activate autophagy as a pro-survival mechanism
under these conditions. The tumor cells also activated auto-
phagy, and its inhibition tended to accelerate their cell death.
What then distinguishes tumorigenic cells from non-tumorigenic
cells that leads to mitochondrial Ca2+ addiction, specifically in
cancer cells? Inhibition of mitochondrial Ca2+ uptake in non-
tumorigenic cells slowed proliferation, whereas it didn’t in the
tumor cell lines. InsP3-mediated Ca
2+ signaling is important in
cell-cycle progression (Ciapa et al., 1994; Han et al., 1992; Miller
et al., 1993; Resende et al., 2010). Conversely, its inhibitionReports 14, 2313–2324, March 15, 2016 ª2016 The Authors 2321
activates AMPK (Ca´rdenas et al., 2010; and discussed in the pre-
sent study), which can phosphorylate and activate p53 to induce
p21waf1/cip1-mediated cell-cycle arrest (Jones et al., 2005). In
contrast, proliferation of the tumor cells examined here was
not slowed by inhibition of InsP3-mediated Ca
2+ signaling.
MCF7 and HeLa cells have mutations in Cdk9 and Cdkn2
(http://lincs.hms.harvard.edu/) that may enable them to bypass
Ca2+-regulated checkpoints. The human fibroblasts we used
were transformed by introducing a constitutively active Cdk4
that phosphorylates Rb independent of Ca2+ signaling. Whereas
several of the cancer cell lines have mutated p53 that could
explain lack of cell-cycle arrest in response to AMPK activation
by InsP3R inhibition, we examined a broad collection of cell lines
with normal and mutated p53 (http://p53.free.fr/index.html), and
they all displayed uninhibited cell-cycle progression. Indeed,
MCF7 and HeLa cells and transformed human fibroblasts that
were used for most of our studies express wild-type p53.
Although AMPK can suppress the mTOR pathway, which plays
a role in coordinating cell growth and the cell cycle (Cuya`s
et al., 2014), AMPK activation induced by InsP3R inhibition
does not affect mTOR activity (Ca´rdenas et al., 2010). Thus, it re-
mains unclear why proliferation was not reduced in tumorigenic
cells in response to inhibition of InsP3R activity. Importantly, pro-
gression into mitosis resulted in catastrophic cell death during
cytokinesis of all the tumor cells examined. Necrosis as the
mechanism of cell death was confirmed by biochemical and his-
tological markers in the cell lines, primary cells, and solid tumors.
In contrast, neither apoptosis nor autophagy, nor necroptosis,
appeared to play significant roles. The mechanisms that lead
to mitotic catastrophic cell death (Vitale et al., 2011) around
the time of cytokinesis remain to be determined. Interactions of
the cyclin-dependent kinase substrate CP110 with Ca2+-binding
proteins calmodulin or centrin are essential for correct cytoki-
nesis. Whereas the presence of a CP110 mutant unable to
bind calmodulin induces cytokinesis failure and multinucleated
cells (Tsang et al., 2006), it is possible that cytokinesis failure in
the face of a bioenergetic crisis results, instead, in necrotic
mitotic catastrophe. The failure of the tumorigenic cells to slow
cell proliferation, despite the fact that they were in an energeti-
cally compromised state, appears to be the major mechanism
that distinguishes them from non-tumorigenic cells and ac-
counts for their susceptibility to cell killing.
In conclusion, using a variety of different tumorigenic cell lines
and isogenic primary transformed human fibroblasts, we have
demonstrated that constitutive InsP3R-mediated Ca
2+ transfer
to mitochondria is essential in maintaining the viability of cancer
cells. In the absence of this signal, normal cells restrict their entry
into the cell cycle, whereas cancer cells bypass the Ca2+ check-
points and undergo a catastrophic necrotic collapse during cyto-
kinesis. Our results reveal a unique mitochondrial addiction to
Ca2+ and a susceptibility of cancer cells that may have therapeu-
tic implications.EXPERIMENTAL PROCEDURES
Reagents
Antibodies were provided as follows. From Cell Signaling Technology:
Phospho-a1-AMPK (Thr172), a1-AMPK, LC3B, HMBG1, ATG7, and cas-2322 Cell Reports 14, 2313–2324, March 15, 2016 ª2016 The Authorpase-3. From BD Biosciences: b-tubulin and InsP3R3. From Sigma: MCU.
InsP3R1 antibody was provided by Dr. R.W. Neumar (University of Michigan).
Secondary antibodies were conjugated with peroxidase from Amersham Bio-
sciences. Chemicals: 3-methyladenine, methyl-pyruvate, dimethyl 2-oxoglu-
tarate, FCCP, oligomycin, rotenone, and Hanks’ balanced salt solution were
purchased from Sigma. Z-VAD-FMK and necrostatin-1 were from Tocris
Bioscience. U73122 and U73343 were from Calbiochem. TOTO-3, DAPI,
cleaved caspase-3 conjugated with FITC, and secondary antibodies conju-
gated with Alexa Fluor 488 were from Molecular Probes. Xestospongin B
was extracted and purified from the marine sponge Xestospongia exigua as
described previously (Ca´rdenas et al., 2005).
Cell Culture and Transfection
Details regarding cell culture and transfection are available in the Supple-
mental Information.
Western Blotting and Treatments
Details of western blotting and cell treatments are available in the Supple-
mental Information.
Microscopy
Details of microscopy are available in the Supplemental Information.
Oxygen Consumption
OCR was measured at 37C using an XF24 extracellular analyzer (Seahorse
Bioscience). Details are provided in the Supplemental Information.
Clonogenic Assay
Colony formation was assayed as described previously (Franken et al., 2006)
with details provided in the Supplemental Information.
Cell Cycle Analysis
Details are provided in the Supplemental Information.
Cell Death
Cell death was determined by LDH activity release by a colorimetric assay
according to the manufacturer’s instructions (Roche) and by PI (final con-
centration, 2.5 mg/ml) exclusion by flow cytometry (BD FACSCanto, BD
Biosciences).
Mouse Tumor Generation and Histochemistry
All in vivo experiments were conducted with the approval of the University of
Pennsylvania Institutional Animal Care and Use Committee. Murine-mela-
noma-derived B16F10 cells (1 3 105 cells) were subcutaneously injected
into flanks of immunodeficient mice, and after 1 week, visible tumors were
observed. Tumors of one flank were injected with 100 ml of a 100-mM XeB
solution, and those on the contralateral side were left untreated or injected
with 1% EtOH in PBS. Mice were euthanized after 1 day or 6 days of treat-
ment with XeB, and tumors were extracted, weighed, and processed for
immunohistochemistry.
Lactate Measurements
Cell lactate was measured colorometrically (Abcam) according to the manu-
facturer’s instructions.
Glucose Uptake
Fibroblasts were washed with Krebs-BSA buffer, pre-incubated (or not) with
cytochalasin B (10 min), and incubated for 10 min at 37C with 10 mM 3H-2-
deoxyglucose. The reaction was stopped by placing it on ice, and the samples
were spun, decanted, lysed in 1% Triton X-100, and cell 3H quantified.
Analysis and Statistics
All data are summarized as means ± SEM; significance of differences was as-
sessed using unpaired Student’s t tests. Differences were accepted as signif-
icant at the 95% level (p < 0.05).s
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and three movies and can be found with this article online at
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